Log in

NASDAQ:TOCATocagen Stock Price, Forecast & News

$1.26
-0.05 (-3.82 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.22
Now: $1.26
$1.50
50-Day Range
$1.18
MA: $3.74
$15.06
52-Week Range
$0.42
Now: $1.26
$6.77
Volume761,400 shs
Average Volume1.47 million shs
Market Capitalization$30.14 million
P/E RatioN/A
Dividend YieldN/A
Beta0.01
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.
Read More
Tocagen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TOCA
CUSIPN/A
Phone858-412-8400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Book Value$0.45 per share

Profitability

Net Income$-63,520,000.00
Net Margins-176,433.34%

Miscellaneous

Employees77
Market Cap$30.14 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive TOCA News and Ratings via Email

Sign-up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.

Tocagen (NASDAQ:TOCA) Frequently Asked Questions

How has Tocagen's stock been impacted by COVID-19 (Coronavirus)?

Tocagen's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TOCA stock has decreased by 18.7% and is now trading at $1.26. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tocagen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tocagen.

When is Tocagen's next earnings date?

Tocagen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tocagen.

How were Tocagen's earnings last quarter?

Tocagen Inc (NASDAQ:TOCA) issued its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative return on equity of 327.74%. View Tocagen's earnings history.

What price target have analysts set for TOCA?

7 Wall Street analysts have issued twelve-month target prices for Tocagen's stock. Their forecasts range from $1.00 to $3.32. On average, they expect Tocagen's share price to reach $1.77 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price. View analysts' price targets for Tocagen.

Has Tocagen been receiving favorable news coverage?

News coverage about TOCA stock has trended negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tocagen earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Tocagen.

Who are some of Tocagen's key competitors?

What other stocks do shareholders of Tocagen own?

Who are Tocagen's key executives?

Tocagen's management team includes the following people:
  • Mr. Martin J. Duvall, CEO & Director (Age 57)
  • Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)
  • Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)
  • Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)
  • Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66)

When did Tocagen IPO?

(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.

What is Tocagen's stock symbol?

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

How do I buy shares of Tocagen?

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tocagen's stock price today?

One share of TOCA stock can currently be purchased for approximately $1.26.

How big of a company is Tocagen?

Tocagen has a market capitalization of $30.14 million and generates $40,000.00 in revenue each year. The company earns $-63,520,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Tocagen employs 77 workers across the globe.

What is Tocagen's official website?

The official website for Tocagen is www.tocagen.com.

How can I contact Tocagen?

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]dvisors.com.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.